Back to Newsroom

Symic Bio Announces Results from MODIFY-OA Trial of SB-061 for the Treatment of Osteoarthritis of the Knee

SAN FRANCISCO, May 18, 2017​ – Symic Bio, a biopharmaceutical company developing novel matrix regulator therapeutics, today announced topline results from the Phase 1/2a MODIFY-OA trial of SB-061, an intra-articular treatment for osteoarthritis of the knee. SB-061 was shown to be safe and very well-tolerated with no drug-related serious adverse events and a very low rate of local adverse events (4.1 percent). Treatment with SB-061 resulted in an approximately 60 percent peak improvement in the Western Ontario and McMaster Universities Arthritis Index pain while walking score (WOMAC A1), the primary efficacy measure, although this measurement did not reach statistical significance relative to the saline control treatment group. In addition, positive trends in synovial fluid biomarker measures (e.g. reduction in inflammatory cytokine TNF-alpha) were observed in the SB-061 treatment group that reinforce the SB-061 intended mechanism of action in human studies for the first time.